Prox1 EMSA Kit
- Known as:
- Prox1 EMSA Kit
- Catalog number:
- GS-0056
- Product Quantity:
- 30 Reactions
- Category:
- -
- Supplier:
- Signosis 2011
- Gene target:
- Prox1 EMSA Kit
Related genes to: Prox1 EMSA Kit
- Gene:
- PROX1 NIH gene
- Name:
- prospero homeobox 1
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 1q32.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-05-18
- Date modifiied:
- 2016-10-05
Related products to: Prox1 EMSA Kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit(1-Kit) 14,15-EET_DHET Hypertension ELISA Kit Related articles to: Prox1 EMSA Kit
- Psoriasis, a persistent inflammatory skin ailment, is distinguished by aberrant γδT17 cell activation. The primary active compound in Bergenia purpurascens, bergenin (Ber), a natural peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, appears to exhibit anti-γδT17 cell activation effects; nevertheless, its therapeutic efficacy for psoriasis remains to be elucidated. - Source: PubMed
Publication date: 2026/05/13
Lin HaochangGuo YileiWan XuanmingHe YueZhu YanrongWei ZhifengXia YufengDai Yue - Rheumatoid arthritis (RA) is a complex autoimmune joint disease characterized by persistent synovial inflammation and hyperplasia. The TNF-α/NF-κB signaling pathway is one of the most important inflammatory pathways involved in the onset and progression of RA. In addition, impaired lymphatic drainage plays a critical role in disease exacerbation. Iguratimod (IGU), a novel disease-modifying antirheumatic drug, has been shown to exert immunomodulatory effects. However, the precise mechanisms underlying its anti-inflammatory function remain unclear. Furthermore, whether IGU could restore lymphatic reflux function in inflammatory arthritis has yet to be determined. Therefore, the study aimed to elucidate the mechanisms underlying the therapeutic effects of IGU in RA. The therapeutic efficacy of IGU was evaluated in a collagen-induced arthritis (CIA) mouse model, with methotrexate used as a positive control. Histopathological analyses of footpad and ankle tissues were performed to asses of disease onset and progression. Levels of inflammatory cytokines (e.g., TNF-α, IFN-γ, IL-4, and IL-6) and IgG autoantibody (such as anti-CCP antibody) were determined using ELISA. Lymphangiogenic markers, including VEGF-C, VEGFR-3, and LYVE-1, were assessed in ankle joint tissues. The protein and mRNA expression levels of TNF-α and NF-κB in joint tissues were also evaluated. In addition, an in vitro tube formation assay was performed to examine the direct effects of IGU on lymphangiogenesis. IGU treatment significantly alleviated arthritis severity in CIA mice by reducing joint inflammation, minimizing tissue damage, and preserving bone integrity. Beyond its established anti-inflammatory properties, IGU could enhance lymphangiogenesis in inflamed joints. Mechanistically, IGU suppressed the TNF-α/NF-κB signaling pathway, thereby attenuating immune responses and inflammatory cytokine production. Furthermore, IGU directly promoted lymphatic vessel formation by upregulating LYVE-1, Prox-1, VEGF-C, and VEGFR-3 in lymphatic endothelial cells. The effect might contribute to the restoration of lymphatic drainage function. The study suggests that IGU exerts a dual therapeutic action by modulating inflammation and promoting lymphatic vessel formation, which might facilitate the restoration of lymphatic drainage and contribute to improved outcomes in RA. - Source: PubMed
Publication date: 2026/05/20
Du MinminXu XiaofenCui XiaohuiChen YilinZhao PengHu QingqingWang CaifengZhang JidaHao GuifengHu Changfeng - Prox-1 (prospero homeobox protein 1) is a master control gene for lymphatic vessel development and it has been widely used as a marker to detect lymphatic vessels inside and outside the eye. We herein report a novel finding of Prox-1 expression on the astrocytes of the optic nerve, a critical structure that conveys visual information from the retina to the brain. We identified that Prox-1 expressing cells were widely distributed inside the optic nerve. These cells co-expressed both GFAP (glial fibrillary acidic protein) and AQP4 (aquaporin-4) which are typical markers for astrocytes. Interestingly, some of the Prox-1+ cells ensheath CD31+ blood vessels inside the optic nerve and these cells are part of the glymphatic system utilized for ocular fluid circulation. This study not only reveals a novel expression pattern of Prox-1 in the optic nerve but also identifies a new marker for the glymphatic system in this critical structure. Further exploration on this novel phenomenon may re-veal new mechanisms and therapeutic targets for optic nerve-related diseases that affect many patients worldwide. - Source: PubMed
Yang YZhang L WZhang L LLi GChen L - PROX1 is a conserved transcription factor with context-dependent roles in cancer. This review evaluates its dual nature as both an oncogenic driver and a tumor suppressor. - Source: PubMed
Publication date: 2026/05/08
Li JiayiLi SongqiangMa JiayiLiu YupuLi TongtongZhou GangYuan Chengfu - Kaposiform lymphangiomatosis (KLA) is an ultrarare disease characterized by abnormal lymphatic vessel proliferation due to hyperactivation of the Rat sarcoma virus (RAS) signaling pathway, resulting in multifocal lymphatic malformations (LMs) that can potentially involve multiple organ systems. Its distinctive histologic features include the presence of clusters of spindle cells expressing clusters of differentiation 31 (CD31), cluster of differentiation 34 (CD34), podoplanin (D2-40), prospero homeobox protein 1 (PROX1), and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), along with abnormal lymphatic vessels. Sirolimus is recommended as a treatment option, particularly for patients without known mutations. This study aimed to examine the long-term therapeutic effects of sirolimus treatment in adult patients with KLA. - Source: PubMed
Publication date: 2026/04/23
Bilny-Paluch MagdalenaPiekarczyk PiotrBłasińska KatarzynaSzołkowska MałgorzataPolaczek MateuszRadzikowska Elżbieta